Latest Peptide News &amp; Research

The Wellness World Is Eager for RFK Jr.'s Promised Move on Peptides

NPR reports that the wellness industry is watching closely as Health Secretary Robert F. Kennedy Jr.'s promised FDA peptide reclassification remains pending weeks after his initial announcement. The universe of peptide providers spans high-end clinics, large wellness chains, med spas, and websites advertising research-grade peptides not intended for human use. While supporters argue the change is necessary to bring consumers to ethical suppliers, critics note these compounds have largely not been tested for safety or efficacy in human trials, with evidence mostly coming from animal studies and cell cultures.

BPC-157IpamorelinMOTS-c

NPRMarch 31, 2026

SemaglutideTirzepatideOrforglipronGLP-1

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

Results from the ATTAIN-MAINTAIN trial show that orforglipron, a novel oral GLP-1 receptor agonist, demonstrated superior weight maintenance compared to placebo in patients transitioning from injectable semaglutide or tirzepatide therapy. The findings suggest patients can successfully switch from injections to an oral formulation without losing their weight loss progress, a significant development for long-term treatment adherence. Orforglipron could represent a major shift in the GLP-1 landscape by offering a convenient pill-based alternative to weekly injections.

HCPLiveMarch 30, 2026

ResearchCritical

GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health

A major new real-world study from Mass General Brigham found that both tirzepatide and semaglutide significantly reduced the risk of heart attack, stroke, and death from any cause. The STEER study found that semaglutide 2.4 mg demonstrated a 57% greater reduction in major cardiovascular adverse events, cardiovascular-related death, or all-cause death compared with tirzepatide. The findings provide critical head-to-head data comparing the two leading GLP-1 receptor agonists on cardiovascular outcomes in real clinical practice.

Mass General BrighamMarch 29, 2026

GLP-1 Agonists Could Be a Global Game-Changer but Need to Be Accessible and Affordable

A comprehensive analysis presented at CROI 2026 shows that popular GLP-1 weight-loss medications generally work well for people living with HIV, and may improve liver, gut, and cardiovascular health while reducing smoking alongside their well-known benefits for obesity and diabetes. The findings expand the therapeutic potential of GLP-1 drugs into infectious disease management. However, researchers and advocates emphasize that cost and access barriers must be addressed for these medications to realize their global public health potential.

aidsmapMarch 28, 2026

SemaglutideLiraglutideGLP-1

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook

NeurologyLive reviews the growing body of evidence for repurposing GLP-1 receptor agonists in neurological conditions including Alzheimer's disease, Parkinson's disease, and sleep disorders. The analysis covers the mechanistic basis for neuroprotection through anti-inflammatory, anti-amyloid, and metabolic pathways, and surveys the expanding clinical trial landscape. Researchers describe GLP-1 receptor agonists as one of the most tractable drug repurposing opportunities for neurodegeneration, though results from ongoing trials remain mixed but promising.

NeurologyLiveMarch 27, 2026

BPC-157TB-500IpamorelinMOTS-c

BPC-157 Is Coming Back: What RFK Jr.'s FDA Peptide Announcement Means for Patients

AgeMD breaks down what the expected FDA reclassification of BPC-157 from Category 2 back to Category 1 means for patients and providers. The article clarifies that reclassification does not equal FDA approval; these peptides will remain off-label therapeutics requiring physician supervision, proper dosing, and ongoing monitoring. With the formal updated list still pending from the FDA, the piece advises patients to work only with licensed compounding pharmacies and qualified medical providers rather than turning to gray-market sources.

AgeMDMarch 27, 2026

BPC-157SemaglutideTirzepatide

Peptides Are Everywhere. RFK Jr. Wants to Make Them Even Easier to Buy

The Wall Street Journal reports on the convergence of surging consumer demand for peptide therapies and the Trump administration's push to ease access under RFK Jr.'s leadership at HHS. The piece examines how peptides marketed for anti-aging, weight loss, and performance enhancement have moved from fringe biohacker circles into mainstream wellness culture. Analysts note that a regulatory rollback could reshape the compounding pharmacy market and accelerate already-rapid industry growth.

WSJMarch 22, 2026

45% keep weight off a year after stopping GLP-1 drugs, study finds

A new study found that 45% of patients maintained meaningful weight loss one year after discontinuing GLP-1 receptor agonist medications, a more optimistic picture than prior research had suggested. Researchers noted that lifestyle adherence, initial magnitude of weight loss, and metabolic factors may influence who sustains results without continued pharmacotherapy. The findings contribute important nuance to the clinical conversation about long-term GLP-1 treatment strategies and expectations.

Medical News TodayMarch 20, 2026

BPC-157TB-500CJC-1295IpamorelinSermorelin

IndustryMedium

Peptide Stacking Is Everywhere—But Should You Be Doing It?

Goop examines the rapidly growing trend of peptide stacking—combining multiple peptide compounds simultaneously to achieve synergistic effects for goals such as fat loss, muscle gain, and anti-aging. The article surveys popular protocols circulating among biohackers and wellness communities while noting the near-total absence of clinical research validating combined peptide regimens. Medical experts quoted in the piece caution that unknown interactions and the unregulated sourcing of many stacked peptides pose real safety concerns.

GoopMarch 26, 2026

Time MagazineFebruary 24, 2026

LongevityMedium

What to Know About the 'Anti-Aging' Peptide Shots Flooding Social Media

Time Magazine investigates the flood of anti-aging peptide injections being promoted across social media platforms by influencers and wellness entrepreneurs. The piece reviews the current scientific evidence—and notable lack thereof—for peptides marketed for longevity, tissue repair, and performance, including compounds like BPC-157 and TB-500. Experts urge consumers to exercise caution as commercial demand and anecdotal promotion far outpaces peer-reviewed evidence in this largely unregulated space.

BPC-157TB-500Epitalon

BPC-157Collagen PeptidesSemaglutide

IndustryMedium

Influencers are promoting peptides for better health. What does the science say?

NPR takes a critical look at the explosion of peptide promotion on social media, where influencers tout everything from BPC-157 to collagen peptides for claims spanning gut healing to muscle recovery and longevity. Scientists and physicians interviewed note that while select peptides have legitimate clinical research behind them, many of the most popular social media claims exceed what the evidence currently supports. The piece highlights a widening regulatory gap that allows many peptide compounds to be sold and promoted with minimal oversight.

NPRFebruary 23, 2026

SemaglutideLiraglutideGLP-1

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis published in Brain and Behavior evaluated GLP-1 receptor agonists as a potential therapeutic strategy for Parkinson's disease, synthesizing data from available clinical trials. The analysis found promising signals for neuroprotective and symptom-modifying effects, building on earlier Phase 2 trial results that showed cognitive and motor benefits in this population. The authors called for larger, adequately powered trials to validate efficacy and determine optimal dosing and treatment duration.

Brain BehavApril 2026

SemaglutideLiraglutideGLP-1

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Published in Nature Aging, this authoritative review by Sabbagh, Cummings, and Ballard examines the growing body of evidence for repurposing GLP-1 receptor agonists in neurodegenerative diseases including Alzheimer's and Parkinson's. The authors outline the mechanistic basis for neuroprotection—including anti-inflammatory, anti-amyloid, and metabolic pathways—and survey the clinical trial landscape currently testing these hypotheses. The paper argues that GLP-1 receptor agonists represent one of the most tractable drug repurposing opportunities for neurodegeneration.

Nature AgingJanuary 2026

7 min read

SemaglutideTirzepatideLiraglutideGLP-1

Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity

This analysis published in ESC Heart Failure evaluated the role of GLP-1 receptor agonists in preventing heart failure hospitalizations and related events in patients with type 2 diabetes and/or obesity. The study adds to accumulating evidence that GLP-1 drugs offer cardiovascular protection that extends beyond glycemic and weight management. Researchers noted variability in effect size across individual agents, suggesting drug-specific rather than class-wide effects may be driving outcomes.

ESC Heart FailMarch 25, 2026

Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity

Using the All of Us research program database, this nested case-control study found a potentially reduced risk of substance use disorders among patients with type 2 diabetes or obesity who were prescribed GLP-1 receptor agonists. The findings align with emerging preclinical and clinical evidence suggesting GLP-1 agents may modulate dopaminergic reward pathways involved in addictive behavior. The research opens a novel translational direction for GLP-1 therapies beyond metabolic disease management.

Front Psychiatry2026

AntioxidantsNovember 21, 2025

LongevityMedium

Ginseng Oligopeptides Promote Longevity and Enhance Stress Resistance in Caenorhabditis elegans via the DAF-16/FOXO Pathway

Researchers demonstrated that ginseng-derived oligopeptides significantly extended lifespan and improved stress resistance in the well-validated model organism C. elegans by activating the DAF-16/FOXO signaling pathway, a conserved longevity cascade also relevant in mammals. The study adds to a growing body of research identifying plant-derived peptides as candidate geroprotective agents with potential for future longevity applications. While findings are preclinical, they provide a mechanistic foundation supporting further investigation of ginseng oligopeptides in aging research.

Ginseng Oligopeptides

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

A new Cleveland Clinic real-world study analyzed outcomes in patients who discontinued GLP-1 receptor agonist therapy, finding rapid weight regain and deterioration of metabolic markers in the months following cessation. The study underscores the chronic-disease nature of obesity and the challenge of long-term adherence to GLP-1 treatment. Researchers emphasize the need for strategies to support sustained use or safe transition planning for patients stopping these medications.

Cleveland Clinic NewsroomMarch 12, 2026

The Clinical Trial VanguardMarch 24, 2026

Patient Dosing Begins in Promising Phase II LSALT Peptide Trial

The Clinical Trial Vanguard reports that patient dosing has commenced in a Phase II trial of the LSALT peptide, targeting acute kidney injury in a cardiac surgery population. LSALT is designed to block the DPP4 receptor on endothelial cells to reduce organ damage from surgical stress and ischemia. The trial's initiation marks a key milestone for Arch BioPartners and represents a novel non-GLP-1 therapeutic peptide moving through clinical development.

LSALT Peptide

3 min read

Clinical ObesityApril 2026

Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD

A secondary analysis of a randomized controlled trial published in Clinical Obesity examined whether liraglutide treatment improved obstructive sleep apnea severity and quality-of-life measures in obese patients who also had COPD. The exploratory findings suggest modest improvements in sleep-related outcomes alongside weight loss, though the study was not powered to confirm these effects. Authors recommend dedicated trials to evaluate GLP-1 receptor agonists as adjunct therapy for respiratory comorbidities of obesity.

Liraglutide

Shoulder ElbowMarch 20, 2026

Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis

Researchers published a propensity-matched analysis in Shoulder & Elbow assessing whether GLP-1 receptor agonist use affects healing outcomes following primary rotator cuff repair in non-diabetic patients. The study addresses growing clinical questions about whether GLP-1 drugs, increasingly used for obesity in non-diabetic populations, influence tendon repair biology or surgical recovery. Results provide early real-world evidence on a clinically relevant but previously unexplored question in orthopedic surgery.

GLP-1

Frontiers in Cardiovascular MedicineMarch 23, 2026

Research on epicardial adipose tissue as a metabolic therapeutic target in AF: focus on GLP-1 receptor agonists

A Frontiers in Cardiovascular Medicine review explores epicardial adipose tissue (EAT) as a driver of atrial fibrillation and examines whether GLP-1 receptor agonists can reduce arrhythmia risk by targeting this metabolically active fat depot. The authors synthesize preclinical and clinical evidence suggesting GLP-1 agonists may reduce EAT volume and associated inflammatory signaling linked to AF onset and recurrence. The review identifies GLP-1 pathway modulation as a promising adjunct strategy in the management of metabolic-driven atrial fibrillation.

GLP-1

Journal of Diabetes and Metabolic DisordersJune 2026

Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis

A real-world cohort study in the Journal of Diabetes and Metabolic Disorders investigated whether GLP-1 receptor agonist use is associated with increased rates of hypersomnolence, or excessive daytime sleepiness. Researchers identified a signal in the data warranting further investigation, as the mechanism may relate to central nervous system effects or changes in sleep architecture secondary to weight loss and metabolic shifts. The findings highlight the importance of monitoring neurological and sleep-related side effects as GLP-1 prescribing continues to expand.

GLP-1

Supercharging the peptide boom

Politico examines the rapidly expanding landscape of peptide therapies in the United States, exploring how policy shifts and growing consumer demand are accelerating the sector's growth. The piece looks at how regulatory changes under the current administration may open doors for broader access to compounded and FDA-regulated peptides. It provides context on the political and commercial forces reshaping how peptides are prescribed, marketed, and regulated.

PoliticoMarch 23, 2026

RegulatoryCritical

RFK Jr. is a 'big fan' of this treatment and plans to widen access

Politico reports that Health and Human Services Secretary RFK Jr. has expressed strong personal support for peptide therapies and is actively working to expand patient access to them. The piece follows recent statements from FDA officials signaling a potential reversal of previous restrictions on compounded peptides. This signals a significant potential shift in federal health policy that could affect how millions of Americans access these treatments.

PoliticoMarch 22, 2026

RetatrutideSemaglutideTirzepatide

Experimental GLP-3 weight-loss drug retatrutide shows promising results in clinical trial

Scientific American covers new clinical trial data on retatrutide, a next-generation triple-hormone receptor agonist sometimes referred to as a GLP-3 drug, showing significant weight loss results in participants. The trial results position retatrutide as a potentially more powerful option than existing GLP-1 medications like semaglutide and tirzepatide. Researchers are optimistic about retatrutide's prospects, though regulatory review and long-term safety data are still pending.

Scientific AmericanMarch 19, 2026

ScienceDailyMarch 20, 2026

BreakthroughHigh

What happens after Ozempic shocked researchers

ScienceDaily covers new research exploring the downstream scientific implications of semaglutide's unexpectedly broad effects on cardiovascular health, addiction, and inflammation, which have prompted researchers to investigate the deeper mechanisms of GLP-1 receptor signaling. Scientists are now probing whether these wide-ranging effects stem from the peptide's direct action on the brain rather than purely metabolic pathways. The findings are reshaping scientific understanding of how GLP-1 drugs work and what other therapeutic applications they may have.

Semaglutide

Haute LivingMarch 20, 2026

LongevityMedium

The Soft Launch Into Longevity: Three Smart Ways to Start Peptide Therapy

Haute Living's Haute MD Network outlines three clinician-recommended entry points for patients interested in incorporating peptide therapies into their longevity and wellness protocols. The piece reviews peptides with evidence supporting cellular repair, hormonal optimization, and metabolic health. It reflects the growing mainstream interest in peptide therapy as a tool for healthy aging, alongside guidance on finding qualified medical supervision.

Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations

A review published in the Journal of the Chinese Medical Association examines emerging clinical evidence linking GLP-1 receptor agonist use to a range of ocular complications, including nonarteritic anterior ischemic optic neuropathy. The authors analyze proposed biological mechanisms by which rapid glycemic changes induced by these drugs may stress optic nerve vasculature. Clinicians are advised to monitor high-risk patients and weigh ocular risks when prescribing GLP-1 therapies.

J Chin Med AssocMarch 17, 2026

Curr Cardiol RepMarch 23, 2026

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications

A review in Current Cardiology Reports assesses the evidence for oral GLP-1 receptor agonists, such as orforglipron and oral semaglutide, in reducing cardiorenal complications including heart failure and chronic kidney disease progression. The authors evaluate how oral formulations compare to injectable counterparts in terms of bioavailability, patient adherence, and clinical outcomes. The findings support expanding oral GLP-1 options as a strategy to improve long-term cardiovascular and renal health in patients with diabetes and obesity.

Semaglutide

J Clin Endocrinol MetabMarch 20, 2026

Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy

A study in the Journal of Clinical Endocrinology & Metabolism evaluates tirzepatide, the dual GIP/GLP-1 receptor agonist, as a treatment option for patients with partial lipodystrophy, a rare disorder of adipose tissue distribution often associated with metabolic complications. Researchers found that tirzepatide improved metabolic parameters in this underserved patient population, suggesting a potential new therapeutic application beyond typical obesity and type 2 diabetes indications. The findings highlight the drug's versatility and could broaden its clinical use.

Tirzepatide

IndustryMedium

TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends

A study published in the Journal of the American Pharmacists Association analyzes how TikTok and broader social media platforms have dramatically amplified public interest in and demand for GLP-1 receptor agonists for weight loss. Researchers examined the content, reach, and accuracy of GLP-1-related posts, finding significant misinformation alongside genuine patient testimonials. The authors call for pharmacists and clinicians to play a more active role in countering misleading social media health claims about these medications.

J Am Pharm AssocMarch 20, 2026

GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research

A narrative review in Sexual Medicine Reviews surveys the emerging body of research on how GLP-1 receptor agonists may influence sexual function in both men and women, noting improvements in libido and erectile function potentially tied to weight loss and reduced inflammation. The authors caution that data remains limited and largely observational, calling for dedicated clinical trials to disentangle direct drug effects from weight-loss-mediated changes. The review identifies sexual health as a meaningful but understudied domain in GLP-1 therapy outcomes.

Sex Med RevJanuary 5, 2026

The Manila TimesMarch 20, 2026

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners has announced that St. Michael's Hospital has begun enrolling and dosing patients in a Phase II clinical trial evaluating LSALT peptide for cardiac surgery-associated acute kidney injury (CS-AKI). The trial marks a significant milestone in moving LSALT peptide from preclinical development into human clinical testing. Results from this study could establish LSALT as a novel peptide-based intervention for a serious and common surgical complication.

LSALT Peptide

3 min read

Ground Truths | Eric TopolJuly 20, 2025

The Peptide Craze

Dr. Eric Topol, a prominent cardiologist and science communicator, published a deep-dive analysis of the surging interest in peptide therapies across both clinical and consumer wellness spaces. The piece examines which peptides have credible scientific backing versus those being promoted ahead of the evidence. Topol's assessment provides a sober, evidence-based framework for evaluating the growing catalog of peptides entering the market.

MedPage TodayMarch 6, 2026

Clinical TrialsMedium

Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta-Analysis

A meta-analysis published in Liver International compared continuous infusion versus bolus dosing of terlipressin, a synthetic vasopressin analogue peptide, in cirrhosis patients experiencing acute oesophageal variceal bleeding or hepatorenal syndrome. The study assessed differences in efficacy and adverse event profiles between the two administration strategies. Findings provide clinicians with evidence-based guidance on optimizing terlipressin dosing in acute liver disease emergencies.

RFK Jr. Says FDA Will Lift Ban on Peptides

Health and Human Services Secretary RFK Jr. announced that the FDA intends to lift its ban on certain compounded peptides, a move that would significantly expand access to peptide therapies for patients. The announcement signals a major regulatory shift for the compounding pharmacy industry and peptide therapy providers. MedPage Today reports this development has drawn both enthusiasm from peptide advocates and caution from medical organizations.